^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR T790M + MET amplification

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor, DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
    Entrez ID:
    1956; 4233
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over2years
    Novel resistance mechanisms to second-generation EGFR tyrosine kinase inhibitor afatinib in non-small cell lung cancer (ESMO 2022)
    Conclusions This study identified multiple genetic factors associated with afatinib efficacy and resistance. In addition, genomic characteristics such as TMB, tumor heterogeneity and APOBEC signature might serve as biomarkers for afatinib response.
    Tumor Mutational Burden
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • TSC2 (TSC complex subunit 2) • ERBB4 (erb-b2 receptor tyrosine kinase 4)
    |
    HER-2 positive • EGFR mutation • HER-2 amplification • PIK3CA mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR T790M • EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR positive • EGFR T790M + MET amplification • HER-2 A775
    |
    Gilotrif (afatinib)
    over2years
    Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer. (PubMed, J Cancer Res Clin Oncol)
    ddPCR is an alternative method to detect MET CNG in both tissues and peripheral blood samples, which is of worthy in clinical promotion.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • EGFR T790M • EGFR T790M + MET amplification
    over2years
    Acquired concurrent EGFR T790M and driver gene resistance from EGFR-TKIs hampered osimertinib efficacy in advanced lung adenocarcinoma (ELCC 2022)
    One patient had acquired EGFR T790M, STRN-ALK fusion, and EGFR amplification after gefitinib progression and was shortly resistant to osimertinib with MET amplification. The other patient developed to acquired EGFR T790M and MET amplification post-dacomitinib and acquired CCDC6-RET fusion after 4-month osimertinib treatment...The T790M accompanying diver gene resistance will be a new subtype after EGFR-TKIs progression and needs effective treatment options. Legal entity responsible for the study The authors.
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • CCDC6 (Coiled-Coil Domain Containing 6) • STRN (Striatin)
    |
    EGFR mutation • HER-2 amplification • MET amplification • EGFR T790M • RET fusion • EGFR amplification • ALK fusion • CCDC6-RET fusion • KRAS G12 • KRAS amplification • STRN-ALK fusion • ALK amplification • EGFR T790M + HER-2 amplification • EGFR T790M + MET amplification
    |
    Tagrisso (osimertinib) • gefitinib • Vizimpro (dacomitinib)